ClinicalTrials.gg
Active, not recruitingNCT04590963INTERLINK-1Updated Sep 9, 2026Results posted

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

A Phase 3 interventional study of Monalizumab and Cetuximab in Squamous Cell Carcinoma of the Head and Neck, sponsored by AstraZeneca. Active, not recruiting at 127 sites in 23 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
370
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca — 4 open to participants now, 6 under way, 2 of them phase 3. Squamous Cell Carcinoma of Head and Neck · AstraZeneca.

Enrollment
4th of 21
370 · median 78
Started
2020
the only one that year
Phase 3
4 of 22
1 open now
Registered
16th of 22
by date

Among the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, this one is the 4th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2020, is one of 4 in phase 3, and was the 16th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

4 of the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, or all of them as a file.
02

Study summary

This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in Participants with recurrent or metastatic head and neck cancer

Read the detailed description

Participants with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who had prior immune checkpoint inhibitor and platinum-based chemotherapy treatment will be randomized in a 2:1 ratio to monalizumab and cetuximab or placebo and cetuximab. Efficacy and safety assessments will be performed periodically from the time of enrollment and throughout the study. Participants in all arms will continue therapy until progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. All Participants will be followed for survival after progression is confirmed.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck

Keywords

  • head and neck cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • monalizumab
  • cetuximab
  • Erbitux
  • oral cavity
  • larynx
  • pharynx
  • natural killer
  • oropharynx
  • hypopharynx
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are aged 18 years and over
  • Recurrent or squamous cell carcinoma of the SCCHN, oral cavity, oropharynx, hypopharynx, or larynx which has progressed on or after previous systemic cancer therapy and is not amenable to curative therapy
  • Received prior treatment using a programmed cell death ligand-1 () inhibitor
  • Prior platinum failure
  • Received 1 or 2 prior systemic regimens for recurrent or metastatic SCCHN
  • Has per 1.1
  • A fresh or recently acquired tumor tissue for the purpose of biomarker testing
  • World Health Organization (WHO)/ (ECOG) Performance Status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Head and neck cancer of any primary anatomic location in the head and neck not specified in the inclusion criteria, including participants with SCCHN of unknown primary or non-squamous histologies
  • Had prior cetuximab therapy (unless it was administered in curative locally advanced setting with radiotherapy and no disease progression for at least 6 months following the last cetuximab dose)
  • Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis
  • Any concurrent anticancer treatment, except for hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
370 participants (actual)

Study arms

  • Experimental
    Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2

    Participants will receive intravenous (IV) monalizumab 750 mg every two weeks (Q2W) and IV cetuximab 400 mg/m\^2 initial dose followed by 250 mg/m\^2 every one week (Q1W) until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.

    Drug: Monalizumab · Drug: Cetuximab

  • Active comparator
    Placebo Q2W + Cetuximab 400 mg/m^2

    Participants will receieve IV placebo matched to monalizumab Q2W and IV cetuximab 400 mg/m\^2 initial dose followed by 250 mg/m\^2 Q1W until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.

    Drug: Cetuximab · Other: Placebo

Interventions

  • Participants will receive IV infusion of monalizumab as stated in arm description.

    Also known as: IPH2201

  • Participants will receive IV infusion of cetuximab as stated in arm description.

    Also known as: Erbitux

  • OtherPlacebo

    Participants will receive IV infusion of placebo as stated in arm description.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set

    The OS is defined as time from the date of randomization until death due to any cause regardless of whether the participant withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization + 1). The OS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and hazard ratio (HR) and confidence intervals (CIs) from a stratified Cox proportional hazards model. Analyses were stratified on World Health Organization/ Eastern Cooperative Oncology Group performance status (WHO/ECOG PS) (0 or 1) and number of prior lines of therapy in recurrent or metastatic (R/M) setting (1 or 2).

    Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)

Secondary outcomes

  1. Overall Survival in Full Analysis Set (FAS)

    The OS is defined as time from the date of randomization until death due to any cause regardless of whether the participant withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization + 1). The OS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on HPV status (OPC HPV positive or HPV-unrelated), WHO/ECOG PS (0 or 1) and number of prior lines of therapy in R/M setting (1 or 2).

    Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)

  2. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment in HPV-unrelated Analysis Set

    PFS per RECIST 1.1 as assessed by the investigator is defined as time from randomization until date of RECIST 1.1-defined radiological progressive disease (PD) or death regardless of whether participant withdraws from therapy or received subsequent anticancer therapy prior to progression. PD: at least 20% increase in sum of diameters of target lesions (TLs), taking as reference the smallest sum on study (nadir) and sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing non-TLs (NTLs) or appearance of new lesions. PFS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on WHO/ECOG PS (0/1) and no. of prior lines of therapy in R/M setting.

    Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)

  3. Progression-Free Survival Per RECIST 1.1 by Investigator Assessment in FAS

    PFS per RECIST 1.1 as assessed by the investigator is defined as time from randomization until date of RECIST 1.1-defined radiological progressive disease (PD) or death regardless of whether participant withdraws from therapy or received subsequent anticancer therapy prior to progression. PD: at least 20% increase in sum of diameters of target lesions (TLs), taking as reference the smallest sum on study (nadir) and sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. PFS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on HPV status, WHO/ECOG PS (0/1) and no. of prior lines of therapy in R/M setting.

    Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)

  4. Percentage of Participants With Objective Response (OR) Per RECIST 1.1 in HPV-unrelated Analysis Set

    The OR is defined as the percentage of participants with at least one confirmed investigator-assessed response of complete response (CR) or partial response (PR) as assessed by RECIST 1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters (SoD) of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. Participants who had measurable disease at baseline per the site investigator were analyzed for this outcome.

    Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)

  5. Percentage of Participants With OR Per RECIST 1.1 in FAS

    The OR is defined as the percentage of participants with at least one confirmed investigator-assessed response of CR or PR as assessed by RECIST 1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. Participants who had measurable disease at baseline per the site investigator were analyzed for this outcome.

    Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)

  6. Duration of Response (DoR) Per RECIST 1.1 in HPV-unrelated Analysis Set

    The DoR is defined as the time from the date of first documented confirmed response until date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as at least a 30% decrease in the SoDs of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in the SoDs of TLs, taking as reference the smallest previous SoDs (nadir) and the sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. The DoR was analyzed using Kaplan-Meier technique.

    Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)

  7. Duration of Response Per RECIST 1.1 in FAS

    The DoR is defined as the time from the date of first documented confirmed response until date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as at least a 30% decrease in the SoDs of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in the SoDs of TLs, taking as reference the smallest previous SoDs (nadir) and the sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. The DoR was analyzed using Kaplan-Meier technique.

    Time frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)

  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.

    Time frame: Day 1 through 21.4 months (maximum observed duration)

  9. Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs

    Participants with abnormal laboratory parameters reported as TEAEs are reported. Laboratory analysis included hematology and clinical chemistry. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.

    Time frame: Day 1 through 21.4 months (maximum observed duration)

  10. Number of Participants With Abnormal Vital Signs Reported as TEAEs

    Participants with abnormal vital signs (heart rate, blood pressure, temperature, and respiratory rate) reported as TEAEs are reported. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.

    Time frame: Day 1 through 21.4 months (maximum observed duration)

  11. Number of Participants With Electrocardiograms (ECGs) Reported as TEAEs

    Participants with Abnormal ECGs reported as TEAEs are reported. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.

    Time frame: Day 1 through 21.4 months (maximum observed duration)

07

Results

Posted Nov 18, 2023
Limitations and caveats
Study enrolment was discontinued after the planned initial interim futility analysis (IA1) due to unlikelihood of achieving statistical significance for OS in the primary endpoint (HPV-unrelated). Therefore, symptoms, function, health-related quality of life (HRQoL), European Organization for Research and Treatment of Cancer (EORTC) scale/item score, pharmacokinetic (PK) parameters, immunogenicity, human leukocyte antigen E (HLA-E), and NKp46+ expression outcomes were not evaluated.

Participant flow

The study was conducted at study sites located in Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, France, Germany, Greece, Italy, Japan, Netherlands, Philippines, Poland, Portugal, Republic of Korea, Russia, Spain, Switzerland, Taiwan, United Kingdom, and United States of America.

Participant flow — Overall Study
MilestoneMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Started247123
Treated246122
Completed00
Not completed247123
Withdrew: Death11859
Withdrew: Lost to follow-up11
Withdrew: Progressive disease01
Withdrew: Study terminated by sponsor10350
Withdrew: Withdrawal by subject158
Withdrew: Ongoing at data cut-off94
Withdrew: Screen failure10

Outcome measures

PrimaryOverall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set

The OS is defined as time from the date of randomization until death due to any cause regardless of whether the participant withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization + 1). The OS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and hazard ratio (HR) and confidence intervals (CIs) from a stratified Cox proportional hazards model. Analyses were stratified on World Health Organization/ Eastern Cooperative Oncology Group performance status (WHO/ECOG PS) (0 or 1) and number of prior lines of therapy in recurrent or metastatic (R/M) setting (1 or 2).

Time frame:
Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Reported as:
Median · Months
Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set
MonthsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set8.8 (6.9 to 10.4)8.6 (6.0 to 14.5)
Statistical analysis
  • Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 vs Placebo Q2W + Cetuximab 400 mg/m^2 · Log Rank · p = 0.989 · Hazard ratio (hr): 1.00 · 95% CI 0.660 to 1.537HR and CIs were calculated using a stratified Cox proportional hazards model, adjusted for WHO/ECOG PS, and number of lines of prior therapy in R/M setting.
SecondaryOverall Survival in Full Analysis Set (FAS)

The OS is defined as time from the date of randomization until death due to any cause regardless of whether the participant withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization + 1). The OS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on HPV status (OPC HPV positive or HPV-unrelated), WHO/ECOG PS (0 or 1) and number of prior lines of therapy in R/M setting (1 or 2).

Time frame:
Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Reported as:
Median · Months
Overall Survival in Full Analysis Set (FAS)
MonthsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Overall Survival in Full Analysis Set (FAS)8.8 (6.9 to 10.8)8.9 (6.0 to 15.1)
Statistical analysis
  • Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 vs Placebo Q2W + Cetuximab 400 mg/m^2 · Log Rank · p = 0.891 · Hazard ratio (hr): 1.03 · 95% CI 0.704 to 1.528HR and CIs were calculated using a stratified Cox proportional hazards model, adjusted for HPV status, WHO/ECOG PS, and number of lines of prior therapy in R/M setting.
SecondaryProgression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment in HPV-unrelated Analysis Set

PFS per RECIST 1.1 as assessed by the investigator is defined as time from randomization until date of RECIST 1.1-defined radiological progressive disease (PD) or death regardless of whether participant withdraws from therapy or received subsequent anticancer therapy prior to progression. PD: at least 20% increase in sum of diameters of target lesions (TLs), taking as reference the smallest sum on study (nadir) and sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing non-TLs (NTLs) or appearance of new lesions. PFS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on WHO/ECOG PS (0/1) and no. of prior lines of therapy in R/M setting.

Time frame:
Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Reported as:
Median · Months
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment in HPV-unrelated Analysis Set
MonthsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment in HPV-unrelated Analysis Set3.6 (3.1 to 3.7)3.8 (2.4 to 4.9)
Statistical analysis
  • Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 vs Placebo Q2W + Cetuximab 400 mg/m^2 · Log Rank · p = 0.574 · Hazard ratio (hr): 1.11 · 95% CI 0.790 to 1.568HR and CIs were calculated using a stratified Cox proportional hazards model, adjusted for WHO/ECOG PS, and number of lines of prior therapy in R/M setting.
SecondaryProgression-Free Survival Per RECIST 1.1 by Investigator Assessment in FAS

PFS per RECIST 1.1 as assessed by the investigator is defined as time from randomization until date of RECIST 1.1-defined radiological progressive disease (PD) or death regardless of whether participant withdraws from therapy or received subsequent anticancer therapy prior to progression. PD: at least 20% increase in sum of diameters of target lesions (TLs), taking as reference the smallest sum on study (nadir) and sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. PFS was analyzed using Kaplan-Meier technique. Statistical analysis was performed using P-value from a stratified log-rank test and HR and CIs from a stratified Cox proportional hazards model. Analyses were stratified on HPV status, WHO/ECOG PS (0/1) and no. of prior lines of therapy in R/M setting.

Time frame:
Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Reported as:
Median · Months
Progression-Free Survival Per RECIST 1.1 by Investigator Assessment in FAS
MonthsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Progression-Free Survival Per RECIST 1.1 by Investigator Assessment in FAS3.5 (2.3 to 3.7)3.7 (2.2 to 4.2)
Statistical analysis
  • Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 vs Placebo Q2W + Cetuximab 400 mg/m^2 · Log Rank · p = 0.530 · Hazard ratio (hr): 1.11 · 95% CI 0.818 to 1.512HR and CIs were calculated using a stratified Cox proportional hazards model, adjusted for HPV status, WHO/ECOG PS, and number of lines of prior therapy in R/M setting.
SecondaryPercentage of Participants With Objective Response (OR) Per RECIST 1.1 in HPV-unrelated Analysis Set

The OR is defined as the percentage of participants with at least one confirmed investigator-assessed response of complete response (CR) or partial response (PR) as assessed by RECIST 1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters (SoD) of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. Participants who had measurable disease at baseline per the site investigator were analyzed for this outcome.

Time frame:
Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response (OR) Per RECIST 1.1 in HPV-unrelated Analysis Set
Percentage of ParticipantsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Percentage of Participants With Objective Response (OR) Per RECIST 1.1 in HPV-unrelated Analysis Set15.2 (0.274 to 1.154)23.9
Statistical analysis
  • Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 vs Placebo Q2W + Cetuximab 400 mg/m^2 · Regression, Logistic · p = 0.115 · Odds ratio (or): 0.56 · 95% CI 0.274 to 1.154The analysis was performed using a logistic regression model, with treatment as a covariate and adjusting for WHO/ECOG PS, and number of lines of prior therapy in the R/M setting with 95% CI calculated by profile likelihood.
SecondaryPercentage of Participants With OR Per RECIST 1.1 in FAS

The OR is defined as the percentage of participants with at least one confirmed investigator-assessed response of CR or PR as assessed by RECIST 1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported. Participants who had measurable disease at baseline per the site investigator were analyzed for this outcome.

Time frame:
Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Reported as:
Number · Percentage of Participants
Percentage of Participants With OR Per RECIST 1.1 in FAS
Percentage of ParticipantsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Percentage of Participants With OR Per RECIST 1.1 in FAS13.1 (0.297 to 1.231)19.1
Statistical analysis
  • Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2 vs Placebo Q2W + Cetuximab 400 mg/m^2 · Regression, Logistic · p = 0.162 · Odds ratio (or): 0.60 · 95% CI 0.297 to 1.231The analysis was performed using a logistic regression model, with treatment as a covariate and adjusting for HPV Status, WHO/ECOG PS, and number of lines of prior therapy in the R/M setting with 95% CI calculated by profile likelihood.
SecondaryDuration of Response (DoR) Per RECIST 1.1 in HPV-unrelated Analysis Set

The DoR is defined as the time from the date of first documented confirmed response until date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as at least a 30% decrease in the SoDs of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in the SoDs of TLs, taking as reference the smallest previous SoDs (nadir) and the sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. The DoR was analyzed using Kaplan-Meier technique.

Time frame:
Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Reported as:
Median · Months
Duration of Response (DoR) Per RECIST 1.1 in HPV-unrelated Analysis Set
MonthsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Duration of Response (DoR) Per RECIST 1.1 in HPV-unrelated Analysis Set5.7 (5.5 to 8.1)5.6 (4.4 to NA)
SecondaryDuration of Response Per RECIST 1.1 in FAS

The DoR is defined as the time from the date of first documented confirmed response until date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as at least a 30% decrease in the SoDs of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in the SoDs of TLs, taking as reference the smallest previous SoDs (nadir) and the sum must demonstrate an absolute increase of at least 5 mm from nadir or unequivocal progression of existing NTLs or appearance of new lesions. The DoR was analyzed using Kaplan-Meier technique.

Time frame:
Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Reported as:
Median · Months
Duration of Response Per RECIST 1.1 in FAS
MonthsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Duration of Response Per RECIST 1.1 in FAS5.7 (5.3 to 8.1)5.6 (4.4 to NA)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.

Time frame:
Day 1 through 21.4 months (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Number of Participants With Treatment-emergent Adverse Events (TEAEs)236120
SecondaryNumber of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs

Participants with abnormal laboratory parameters reported as TEAEs are reported. Laboratory analysis included hematology and clinical chemistry. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.

Time frame:
Day 1 through 21.4 months (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs
ParticipantsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Anaemia3515
Anaemia folate deficiency10
Hypochromic anaemia10
Iron deficiency anaemia10
Leukocytosis32
Leukopenia01
Lymphocytosis01
Lymphopenia31
Neutropenia11
Neutrophilia02
Normocytic anaemia10
Thrombocytopenia10
Thrombocytosis12
Hyperthyroidism01
Hypoparathyroidism10
Hypothyroidism157
Hyperamylasaemia10
Hypercalcaemia74
Hyperglycaemia75
Hyperkalaemia31
Hyperlipasaemia10
Hypermagnesaemia31
Hyperphosphataemia10
Hypoalbuminaemia24
Hypocalcaemia114
Hypoglycaemia10
Hypokalaemia139
Hypomagnesaemia4221
Hyponatraemia63
Hypophosphataemia98
Iron deficiency10
Activated partial thromboplastin time prolonged10
Alanine aminotransferase increased75
Amylase increased63
Aspartate aminotransferase increased74
Blood alkaline phosphatase increased73
Blood beta-D-glucan increased01
Blood bilirubin increased30
Blood creatine phosphokinase increased20
Blood creatinine increased63
Blood iron decreased01
Blood lactate dehydrogenase increased33
Blood phosphorus decreased10
Blood potassium decreased10
Blood thyroid stimulating hormone abnormal10
Blood thyroid stimulating hormone increased23
Blood urea increased01
C-reactive protein increased02
Gamma-glutamyltransferase increased51
Inflammatory marker increased10
International normalised ratio increased10
Lipase increased122
Lymphocyte count decreased30
Neutrophil count decreased23
Neutrophil count increased10
Platelet count decreased10
Platelet count increased10
Transaminases increased10
White blood cell count decreased23
White blood cell count increased10
Dyslipidaemia01
SecondaryNumber of Participants With Abnormal Vital Signs Reported as TEAEs

Participants with abnormal vital signs (heart rate, blood pressure, temperature, and respiratory rate) reported as TEAEs are reported. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.

Time frame:
Day 1 through 21.4 months (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Reported as TEAEs
ParticipantsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Hypertension44
Hypotension113
Hypoxia01
Hyperpyrexia10
Pyrexia1810
SecondaryNumber of Participants With Electrocardiograms (ECGs) Reported as TEAEs

Participants with Abnormal ECGs reported as TEAEs are reported. TEAEs included events from the first dose of study drug, up to 90 days after the last dose of study drug received or up to the start date of any subsequent anticancer therapy following discontinuation of study drug, or the final safety DCO date of 01Sep2022, whichever occurred first.

Time frame:
Day 1 through 21.4 months (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiograms (ECGs) Reported as TEAEs
ParticipantsMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Electrocardiogram QT prolonged10
Arrhythmia01
Atrial fibrillation10
Sinus tachycardia20
Tachycardia22
Ventricular arrhythmia01

Adverse events

Collected over Day 1 through 21.4 months (maximum observed duration). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2120/247 (48.6%)77/246 (31.3%)213/246 (86.6%)
Placebo Q2W + Cetuximab 400 mg/m^261/123 (49.6%)27/122 (22.1%)111/122 (91%)
Most frequent serious events
Showing 10 of 88
Most frequent serious events
EventMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
PneumoniaInfections and infestations13/2468/122
Infusion related reactionInjury, poisoning and procedural complications2/2463/122
Covid-19Infections and infestations5/2461/122
PneumonitisRespiratory, thoracic and mediastinal disorders1/2462/122
PyrexiaGeneral disorders4/2460/122
SepsisInfections and infestations4/2460/122
StomatitisGastrointestinal disorders3/2460/122
Pneumonia aspirationInfections and infestations3/2461/122
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/2460/122
Venous thrombosisVascular disorders0/2461/122
Most frequent other events
Showing 10 of 30
Most frequent other events
EventMonalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2
Dermatitis acneiformSkin and subcutaneous tissue disorders80/24642/122
RashSkin and subcutaneous tissue disorders56/24627/122
FatigueGeneral disorders48/24620/122
HypomagnesaemiaMetabolism and nutrition disorders42/24620/122
NauseaGastrointestinal disorders26/24620/122
ParonychiaInfections and infestations28/24619/122
PruritusSkin and subcutaneous tissue disorders32/24618/122
AnaemiaBlood and lymphatic system disorders33/24615/122
ConstipationGastrointestinal disorders33/24611/122
StomatitisGastrointestinal disorders31/24616/122

Baseline characteristics

Baseline analysis population included all participants randomized up to the safety DCO date of 01Sep2022.

Age, Continuous
Age, Continuous(Years)Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2Total
Mean62.0 ± 10.461.4 ± 9.661.8 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2Total
Female422971
Male20594299
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2Total
Hispanic or Latino12517
Not Hispanic or Latino223114337
Unknown or Not Reported12416
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Monalizumab 750 mg Q2W + Cetuximab 400 mg/m^2Placebo Q2W + Cetuximab 400 mg/m^2Total
American Indian or Alaska Native000
Asian663096
Native Hawaiian or Other Pacific Islander000
Black or African American303
White16989258
More than one race000
Unknown or Not Reported9413
08

Study locations

127 sites
  • Research Site
    Tucson, Arizona 85719, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Westwood, Kansas 66205, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Las Vegas, Nevada 89169, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    CABA, 1426, Argentina
  • Research Site
    CABA, C1012AAR, Argentina
  • Research Site
    CABA, C1426ANZ, Argentina
  • Research Site
    Camperdown, 2050, Australia
  • Research Site
    Elizabeth Vale, 5112, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Linz, 4010, Austria
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Belo Horizonte, 30110-022, Brazil
  • Research Site
    Porto Alegre, 90560-030, Brazil
  • Research Site
    Rio de Janeiro, 22271-110, Brazil
  • Research Site
    São Paulo, 01321-001, Brazil
  • Research Site
    São Paulo, 01327-001, Brazil
  • Research Site
    São Paulo, 01509-900, Brazil
  • Research Site
    São Paulo, 04543-000, Brazil
  • Research Site
    Panagyurishte, 4500, Bulgaria
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Victoria, British Columbia V8R 6V5, Canada
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Avignon, 84918, France
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Clermont-Ferrand, 63011, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Lyon, 69373, France
  • Research Site
    Marseille, 13005, France
  • Research Site
    Montpellier, 34298, France
  • Research Site
    Strasbourg, 67033, France
  • Research Site
    Berlin, 12203, Germany
  • Research Site
    Essen, 45122, Germany
  • Research Site
    Freiburg im Breisgau, 79106, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Würzburg, 97070, Germany
  • Research Site
    Athens, 11528, Greece
  • Research Site
    Chaïdári, 124 62, Greece
  • Research Site
    Thessaloniki, 54645, Greece
  • Research Site
    Brescia, 25123, Italy
  • Research Site
    Candiolo, 10060, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Modena, 41124, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Fukuoka, 811-1395, Japan
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Isehara-shi, 259-1193, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Kobe, 650-0017, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Okayama, 700-8558, Japan
  • Research Site
    Sayama, 589-8511, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Yokohama, 236-0004, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Amsterdam, 1066 CX, Netherlands
  • Research Site
    Maastricht, 6229 HX, Netherlands
  • Research Site
    Nijmegen, 6525 GA, Netherlands
  • Research Site
    Manila, 1000, Philippines
  • Research Site
    Pasig, 1605, Philippines
  • Research Site
    Quezon City, 1112, Philippines
  • Research Site
    Bialystok, 15-027, Poland
  • Research Site
    Bydgoszcz, 85-796, Poland
  • Research Site
    Poznan, 61-866, Poland
  • Research Site
    Coimbra, 3000-075, Portugal
  • Research Site
    Porto, 4099-001, Portugal
  • Research Site
    Porto, 4200-319, Portugal
  • Research Site
    Vila Nova de Gaia, 4434-502, Portugal
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow Region, 143081, Russia
  • Research Site
    Obninsk, 249036, Russia
  • Research Site
    Saint Petersburg, 191014, Russia
  • Research Site
    Saint Petersburg, 195271, Russia

Showing the first 100 of 127 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nowojewski A, Wheal A, Dott W, Ruscica D, Ghiorghiu S, Valastro B. Implementation of the Study Participant Feedback Questionnaire to understand participant experience in a phase 3 oncology clinical trial. BMJ Open. 2025 Oct 28;15(10):e094596. doi: 10.1136/bmjopen-2024-094596. PubMed 41151963 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of the timelines, please refer to the disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in May 2022, 19 months.

Results were first posted in Nov 2023, 1 year 6 months after primary completion. A results delay was requested in May 2023.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2020
First posted
Oct 19, 2020
StartActual
Oct 2, 2020
Primary completionActual
May 11, 2022
CompletionEst.
Sep 24, 2026
Results delay requested
May 10, 2023
Results first posted
Nov 18, 2023
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04590963
Lead sponsor
AstraZeneca
Collaborators
Innate Pharma
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Oct 2, 2020
Primary completion
May 11, 2022
Completion
Sep 24, 2026 (estimated)
Results posted
Nov 18, 2023
Last update
Sep 9, 2026

Study contacts

Roger B Cohen, MD
principal investigator · Abramson Cancer Center, Perelman Center for Advanced Medicine
Jérôme Fayette, MD
principal investigator · Centre Leon Berard
Dario Ruscica, MD
study director · AstraZeneca, Cambridge, UK

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Monalizumab

Start the discussion